Infertility treatment heads first drugs on FDA’s new priority review scheme
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results …
Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev …
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than …
The US Food and Drug Administration’s (FDA’s) pilot scheme to expedite the review of US-made generic medicines is welcomed but …
France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline …
Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand …
AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to …
Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset, …
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every …
Bavarian Nordic’s board of directors has urged shareholders to accept a sweetened takeover offer as the potential sale of the …
Tubulis has completed a Series C financing round, securing €308m ($361m) that will primarily be directed towards advancing clinical development …
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m …